Structure via PubChem · Public domain (PubChem)
baricitinib
Sign in to saveBaricitinib, sold under the brand name Olumiant among others, is an immunomodulatory medication used for the treatment of rheumatoid arthritis, alopecia areata, and COVID-19. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.
Key facts
- Drug.MedlinePlus
- a618033
- Drug.DailyMedID
- Baricitinib
- Drug.pregnancy_AU
- D
- Drug.pregnancy_category
- Use is contraindicated
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AF02
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.bioavailability
- 79%
- Drug.protein_bound
- 50%
- Drug.metabolism
- CYP3A4 (<10%)
- Drug.elimination_half life
- 12.5 hours
- Drug.excretion
- 75% urine, 20% faeces
- Drug.CAS_number
- 1187594-09-7
via Wikipedia infobox
Chemical data
- Formula
- C16H17N7O2S
- Molecular weight
- 371.4 g/mol
- IUPAC name
- 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
- SMILES
- CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
- InChIKey
- XUZMWHLSFXCVMG-UHFFFAOYSA-N
- XLogP
- -0.5
- Polar surface area
- 129 Ų
- H-bond donors
- 1
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Research
2,410 papers- Two Phase 3 Trials of Baricitinib for Alopecia Areata.The New England journal of medicine · 2022
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.The New England journal of medicine · 2017
- Baricitinib for the Treatment of Alopecia Areata.Drugs · 2023
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).American journal of clinical dermatology · 2023
- Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes.The New England journal of medicine · 2023
via PubMed
Wikidata facts
- Mass
- 371.116443784
Show 4 more facts
- chemical formula
- C₁₆H₁₇N₇O₂S
- canonical SMILES
- CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
- defined daily dose
- 4
- Commons category
- Baricitinib
Sources (7)
via Wikidata · CC0
~13 min read
Article
16 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- Society and culture
- Legal status
- Research
- Alopecia areata
- COVID-19
- HIV/AIDS
- References
- Further reading
Baricitinib, sold under the brand name Olumiant among others, is an immunomodulatory medication used for the treatment of rheumatoid arthritis, alopecia areata, and COVID-19. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.
Baricitinib is approved for medical use in the European Union and in the United States.
Gallery (2)
Connections
biological half-life
Entity
tirzepatide
Entity
immunosuppressive drug
Entity
tadalafil
Entity
interferon gamma
Entity
peginterferon alfa-2a
Entity
Insulin Lispro
Entity
interferon type I
Entity
ixekizumab
Entity
glucagon
Entity
JAK1
Gene
JAK2
Gene
momelotinib
Entity
lumiliximab
Entity
Janus kinase 3
Protein
lebrikizumab
Entity
COVID-19
Entity
World Health Organization
Entity
medication
Entity
metabolism
Entity